Compare SGMT & RAAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SGMT | RAAQ |
|---|---|---|
| Founded | 2006 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.2M | 237.8M |
| IPO Year | 2023 | 2025 |
| Metric | SGMT | RAAQ |
|---|---|---|
| Price | $6.35 | $10.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $29.71 | N/A |
| AVG Volume (30 Days) | ★ 504.2K | 23.8K |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $9.62 |
| 52 Week High | $11.41 | $10.83 |
| Indicator | SGMT | RAAQ |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | N/A |
| Support Level | $5.95 | N/A |
| Resistance Level | $6.42 | N/A |
| Average True Range (ATR) | 0.31 | 0.00 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 77.04 | 0.00 |
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Real Asset Acquisition Corp is a blank check company.